FRI0190 Relationship between faecal calprotectin, hlab-27 and acute phase reactants in patients with spondyloarthritis without prior diagnosis of inflammatory bowel disease. (12th June 2018)

• Record Type: Journal Article
• Authors: Ramos Giraldez, C.; Espinosa Malpartida, M.; Merino Argumánez, C.; Ruíz Antorán, B.; Campos Esteban, J.; Barbadillo Mateos, C.; Godoy Tundidor, H.; Agudo Castillo, B.; González Lama, Y.; Andréu Sánchez, J.L.; Sanz Sanz, J.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 636
• Page End: 636
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.5902
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Faecal calprotectin (FC) is a biomarker of inflammatory bowel activity widely used in the diagnosis and follow-up of inflammatory bowel disease (IBD). Microscopic intestinal inflammation is described in approximately 50% of patients with spondyloarthritis (SpA), and it is associated with more severe disease. Objectives: The purpose of this study was to describe the possible relationship between FC, HLAB27 and acute phase reactants in patients diagnosed of SpA without clinical suspicion or prior diagnosis of IBD. Methods: Unicentric, cross-sectional observational study with prospective clinical data collection. We included consecutively selected patients in the Rheumatology Clinic diagnosed of SpA who fulfilled ASAS criteria and did not have digestive symptoms suggestive of IBD (chronic diarrhoea, rectal bleeding, perianal disease or chronic abdominal pain persistent/recurrent). Demographic, clinical and analytical data from SpA (Uveitis, HLAB27, acute phase reactants), treatments and FC were collected and a FC cut-off point >50 MG/kg was determined. For patients on NSAIDS suspension was recommended two weeks prior to collection of stool samples. The study was approved by the centre's Ethics Committee for Clinical Trials. Results: Ninety-nine patients were included. 50% male, average age 46±11 years old. 3.7±2.5 BASDAI. 79% HLA-B27 positive, 31% had elevated levels of ESR, 9% elevated CRP (>10 mg/L). 49 patients (49.5%) had high levels of FC, with mean levels of 276 mg/Kg (range 52–3, 038). HLAB27 positive patients had significantly higher FC levels than HLAB27 negative patients (160 mg/kg vs 98 mg/kg; p<0.05). There were no differences in relation to the history of uveitis. Patients with high FC had significantly higher CRP levels than patients with normal FC (6.7 mg/L vs. 3.2 mg/L; p<0.05), in accordance with these results from the group of patients with CRP levels>10 mg/L, the percentage of FC elevation was 78% vs. 47% of patients with CRP <10 mg/L. There were no significant differences in relation to ESR. Conclusions: Patients with spondyloarthritis (ASAS criteria), HLAB27 positive and elevated CRP have higher levels of faecal calprotectin, a biomarker of inflammatory bowel activity, which may indicate that inflammatory activity in SpA might be associated with subclinical intestinal inflammation. Disclosure of Interest: None declared